Want to see JP:4524 full AI Analyst Report?
Top Page
Morishita Jintan Co., Ltd.
(4524)
Select Model
Select Model
Rating:69Neutral
Price Target:
¥2,460.00
▲(12.48% Upside)
Action:Reiterated
Date:08/17/26
The score is driven primarily by solid underlying financial stability (notably a conservative balance sheet) offset by uneven cash conversion and a recent revenue dip. Technicals are supportive with a clear uptrend, though near-overbought signals limit upside in the near term. Valuation adds support via a moderate P/E and a ~2.9% dividend yield.
Positive Factors
Conservative Balance Sheet
Low leverage and a large equity cushion reduce solvency risk and give the company room to fund product development or absorb volatility. The 2026 debt increase bears monitoring, but current capitalization supports resilience over the next several quarters.
Negative Factors
Recent Revenue Contraction
The latest top-line decline signals a pause in demand or market expansion and creates a weaker starting point for near-term growth. Sustained contraction could reduce operating leverage and limit the company’s ability to improve profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Low leverage and a large equity cushion reduce solvency risk and give the company room to fund product development or absorb volatility. The 2026 debt increase bears monitoring, but current capitalization supports resilience over the next several quarters.
Read all positive factors
Morishita Jintan Co., Ltd. (4524) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥9.15B
Dividend Yield2.9%
Average Volume (3M)1.68K
Price to Earnings (P/E)11.6
Beta (1Y)0.33
Revenue Growth0.98%
EPS Growth69.36%
CountryJP
Employees359
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)192.52
Shares Outstanding4,150,000
10 Day Avg. Volume1,530
30 Day Avg. Volume1,680
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)0.70
Price to Sales (P/S)0.72
P/FCF Ratio506.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Morishita Jintan Co., Ltd. Business Overview & Revenue Model
Company Description
Morishita Jintan Co., Ltd. is a Japanese enterprise that manufactures and distributes a diverse array of products, encompassing pharmaceuticals, quasi-pharmaceuticals, medical devices, and food items. The company's operations are divided into two ...
How the Company Makes Money
null...
Morishita Jintan Co., Ltd. Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
78
Positive
Cash Flow
57
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.82B | 12.69B | 12.77B | 12.41B | 11.36B | 9.56B |
| Gross Profit | 6.23B | 5.93B | 5.79B | 6.00B | 5.31B | 4.88B |
| EBITDA | 1.54B | 1.29B | 1.36B | 1.29B | 1.25B | 977.00M |
| Net Income | 789.00M | 628.00M | 547.00M | 697.00M | 491.00M | 283.00M |
Balance Sheet | ||||||
| Total Assets | 18.62B | 18.62B | 17.90B | 17.18B | 16.10B | 14.48B |
| Cash, Cash Equivalents and Short-Term Investments | 1.52B | 1.83B | 1.94B | 1.09B | 2.41B | 2.14B |
| Total Debt | 1.75B | 1.76B | 1.36B | 270.00M | 469.00M | 749.00M |
| Total Liabilities | 5.65B | 5.64B | 5.74B | 5.04B | 4.71B | 4.02B |
| Stockholders Equity | 12.97B | 12.98B | 12.15B | 12.14B | 11.39B | 10.46B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 18.00M | 69.00M | -455.00M | 715.00M | -159.00M |
| Operating Cash Flow | 0.00 | 1.15B | 669.00M | 196.00M | 1.18B | 543.00M |
| Investing Cash Flow | 0.00 | -1.23B | -701.00M | -1.15B | -474.00M | -463.00M |
| Financing Cash Flow | 0.00 | -30.00M | 880.00M | -362.00M | -433.00M | -645.00M |
Morishita Jintan Co., Ltd. Technical Analysis
Positive
2187.00
Price Trends
2193.92
Positive
2193.13
Positive
2178.94
Positive
Market Momentum
13.71
Positive
63.40
Neutral
50.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4524, the sentiment is Positive. The current price of 2187 is below the 20-day moving average (MA) of 2231.85, below the 50-day MA of 2193.92, and above the 200-day MA of 2178.94, indicating a bullish trend. The MACD of 13.71 indicates Positive momentum. The RSI at 63.40 is Neutral, neither overbought nor oversold. The STOCH value of 50.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4524.
Morishita Jintan Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ¥9.15B | 11.64 | ― | 2.55% | 0.98% | 69.36% | |
65 Neutral | ¥292.95B | 9.34 | 9.29% | 3.87% | 10.38% | 19.96% | |
64 Neutral | ¥20.26B | 8.95 | ― | 3.71% | 2.29% | ― | |
59 Neutral | ¥10.69B | 31.64 | ― | 1.06% | 25.89% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | ¥17.90B | 41.98 | ― | 4.37% | 8.42% | 49.52% |
* Healthcare Sector Average
JP:4524
Morishita Jintan Co., Ltd.
2,240.00
91.63
4.26%
JP:4540
Tsumura & Co
3,784.00
376.25
11.04%
JP:2929
Pharma Foods International Co., Ltd.
618.00
-303.35
-32.92%
JP:4512
Wakamoto Pharmaceutical Co., Ltd.
312.00
6.57
2.15%
JP:4538
Fuso Pharmaceutical Industries,Ltd.
2,298.00
225.46
10.88%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.